阿托伐他汀钙片联合厄贝沙坦氢氯噻嗪片治疗原发性高血压的效果及安全性  

Efficacy and safety of atorvastatin calcium tablets combined with irbesartan hydrochlorothiazide tablets in the treatment of essential hypertension

作　　者：刘洋 徐笑群 LIU Yang;XU Xiaoqun(Department of Pharmacy,Linyi Central Hospital,Shandong Province,Linyi 276400,China)

机构地区：[1]山东省临沂市中心医院药学部,276400

出　　处：《临床合理用药》2025年第11期12-15,共4页Chinese Journal of Clinical Rational Drug Use

基　　金：临沂市重点研发计划(医学类)(2023YX0112)。

摘　　要：目的观察阿托伐他汀钙片联合厄贝沙坦氢氯噻嗪片治疗原发性高血压的效果及安全性。方法选取2022年10月—2023年10月临沂市中心医院收治的原发性高血压患者95例,依据多阶段抽样法分为试验组(n=49)和对照组(n=46)。对照组单纯给予厄贝沙坦氢氯噻嗪片治疗,试验组在对照组基础上给予阿托伐他汀钙片治疗,2组均接受3个月治疗。比较2组疗效,治疗前后收缩压(SBP)、舒张压(DBP)、脉压(PP)、一氧化氮(NO)、血管内皮素-1(ET-1)、血浆黏度(PV)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平及不良反应。结果试验组总有效率为97.96%,高于对照组的84.78%(χ^(2)=5.341,P=0.020)。治疗3个月后,2组SBP、DBP、PP均低于治疗前,且试验组低于对照组(P<0.01);2组NO水平高于治疗前,ET-1水平及PV低于治疗前,且试验组变化幅度大于对照组(P<0.01);2组TC、TG、LDL-C水平低于治疗前,HDL-C水平高于治疗前,且试验组变化幅度大于对照组(P<0.01)。试验组不良反应总发生率为4.08%,低于对照组的17.39%(χ^(2)=4.462,P=0.034)。结论阿托伐他汀钙片联合厄贝沙坦氢氯噻嗪片治疗原发性高血压能取得更显著的临床效果,可有效降低血压,调节血脂及血液黏度,改善血管内皮功能,且安全性较高。Objective To observe the efficacy and safety of atorvastatin calcium tablets combined with irbesartan hydrochlorothiazide tablets in the treatment of essential hypertension.Methods A total of 95 patients with essential hypertension treated in Linyi Central Hospital from October 2022 to October 2023 were selected and divided into experimental group(n=49)and control group(n=46)according to multi-stage sampling method.The control group was treated with irbesartan hydrochlorothiazide tablets alone,and the experimental group was treated with atorvastatin calcium tablets on the basis of the control group.Both groups received treatment for 3 months.The efficacy,SBP,DBP,PP,PV,the levels of NO,ET-1,TC,TG,LDL-C,HDL-C before and after treatment,and adverse reactions of two groups were compared.Results The total effective rate of the experimental group was 97.96%,which was higher than 84.78%of the control group(χ^(2)=5.341,P=0.020).After 3 months of treatment,SBP,DBP and PP in two groups were lower than before treatment,and the experimental group were lower than the control group(P<0.01).The levels of NO in two groups were higher than before treatment,the level of ET-1 and PV were lower than before treatment,and the change range of experimental group were greater than those of control group(P<0.01).The levels of TC,TG and LDL-C in two groups were lower than before treatment,and the level of HDL-C were higher than before treatment,and the change range of experimental group were greater than those of control group(P<0.01).The total incidence of adverse reactions in experimental group was 4.08%,which was lower than 17.39%of control group(χ^(2)=4.462,P=0.034).Conclusion Atorvastatin calcium tablets combined with irbesartan hydrochlorothiazide tablets can achieve more significant clinical effects in the treatment of essential hypertension,which can effectively reduce blood pressure,regulate blood lipids and blood viscosity,improve vascular endothelial function with high safety.

关 键 词：原发性高血压 阿托伐他汀钙片 厄贝沙坦氢氯噻嗪片 血压 血脂 不良反应 

分 类 号：R54[医药卫生—心血管疾病]